SC75741

Catalog No.S7273 Batch:S727301

Print

Technical Data

Formula

C29H23N7O2S2
Molecular Weight 565.67 CAS No. 913822-46-5
Solubility (25°C)* In vitro DMSO 41 mg/mL (72.48 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SC75741 is a potent NF-κB inhibitor with EC50 of 200 nM. SC75741 efficiently blocks influenza virus propagation.
Targets
NF-κB [1]
(Cell-based NF-κB reporter gene assay)
200 nM(EC50)
In vitro SC75741 shows immunosuppressive activity by inhibiting human PBMC proliferation with IC50 of 2.2 μM. [1] SC75741 inhibits replication of influenza A and B viruses by inhibiting NF-κB-mediated signalling on a transcriptional level. Moreover, SC75741 shows a high barrier for development of resistant virus variants. [2]
In vivo SC75741 (15 mg/kg i.p.) reduces virus replication and cytokine expression in mice lungs after H5N1 influenza virus infection. [2]
Features NF-κB-selective inhibitor.

Protocol (from reference)

Kinase Assay:[1]
  • NF-κB reporter gene assay

    The NF-κB reporter gene assay is prepared with A549-NF-κB-SEAP cell line according to manufacturer’s instructions. In short, A549 cells stably transfected with pNF-κB-SEAP reporter gene plasmid are plated and allowed to attach overnight. The cells are subsequently incubated for 5 h with described compounds at 100, 30, 10, 3, 1, 0.3, 0.1, and 0 μM and then stimulated with 10 ng/ml TNF-α for 22 h. The supernatant of the cell is analyzed for SEAP activity using a chemiluminescent SEAP reporter gene assay.
Cell Assay:[1]
  • Cell lines

    Human PBMCs

  • Concentrations

    ~50 μM

  • Incubation Time

    48 hours

  • Method

    Cell viability assay is prepared using a CellTiter-BluTM Cell Viability Assay. For each concentration of the compound four replicates are measured.
Animal Study:[2]
  • Animal Models

    C57BL/6 mice infected with H5N1 influenza virus

  • Dosages

    ~15 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Oncotarget, 2016, 7(32):52281-52293]

Data from [Data independently produced by , , J Nutr Biochem, 2016, 41:56-64. ]

Data from [Data independently produced by , , J Nutr Biochem, 2017, 41:56-64]

Data from [Data independently produced by , , Biomed Pharmacother, 2019, 109:1978-1987]

Selleck's SC75741 has been cited by 51 publications

Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer [ J Transl Med, 2024, 22(1):672] PubMed: 39033271
Hepatocyte growth factor enhances the ability of dental pulp stem cells to ameliorate atherosclerosis in apolipoprotein E-knockout mice [ World J Stem Cells, 2024, 16(5):575-590] PubMed: 38817328
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth [ J Exp Clin Cancer Res, 2023, 42(1):25] PubMed: 36670508
A Disintegrin and Metalloproteinase with Thrombospondin Motifs 4 Regulates Pulmonary Vascular Hyperpermeability through Destruction of Glycocalyx in Acute Respiratory Distress Syndrome [ Int J Mol Sci, 2023, 10.3390/ijms242216230] PubMed: 38003418
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment [ Nat Commun, 2022, 13(1):4261] PubMed: 35871223
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment [ Nat Commun, 2022, 13(1):4261] PubMed: 35871223
Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli [ Front Immunol, 2022, 13:990077] PubMed: 36405746
Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages Toward M1 Through NF-κB/NLRP3 Signaling [ Front Immunol, 2022, 13:839460] PubMed: 35603205
Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli [ Front Immunol, 2022, 13:990077] PubMed: 36405746
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors [ Oncoimmunology, 2022, 11(1):2109861] PubMed: 35979386

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.